Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness
Crossref DOI link: https://doi.org/10.1186/s40064-015-1441-5
Published Online: 2015-10-23
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kast, R. E.
License valid from 2015-10-23